Die Behandlung mit Psychopharmaka in der Schwangerschaft – Teil I: So wenig wie möglich, aber so viel wie nötig

Lernziele

Der Text soll dem Leser einen Überblick über die aktuelle Studienlage zu Embryo- und Fetotoxizität der bei psychischen Störungen verwendeten Psychopharmaka vermitteln. Der Leser soll in der Lage sein, bei der Nutzen-Risiko-Abwägung bezüglich der Gabe eines Psychopharmakons in der Schwangerschaft die relevanten Aspekte zu berücksichtigen und neben möglichen Einflüssen auf das Kind die mütterlichen Faktoren einzubeziehen.

Literatur

• 1 Monitor Familienleben 2010. Allensbach: Institut für Demoskopie; 2010 Im Internet http://www.ifd-allensbach.de ; Stand: 25.04.2011
• 2 Marneros A, Deister A, Rohde A. Affektive, schizoaffektive und schizophrene Psychosen. Berlin: Springer; 1991
• 3 Rohde A. Psychische Störungen und Reproduktion. In: Marneros A, Rohde A, (Hrsg) Geschlechtsspezifische Psychiatrie und Psychotherapie.. Stuttgart: Kohlhammer; 2007: 512-519
• 4 Krumm S, Kilian R, Becker T. „Ich werde sie sicherlich nicht einfach so in die Welt setzen …“. Der soziale Kontext des Kinderwunschs aus der Sicht von Frauen mit psychischen Erkrankungen.  Psychiat Prax. 2011;  38 23-30
• 5 Kendell R E, Chalmers J C, Platz C. Epidemiology of puerperal psychoses.  Br J Psychiatry. 1987;  150 662-673
• 6 Harlow B L, Vitonis A F, Sparen P et al. Incidence of hospitalization for postpartum psychotic and bipolar episodes in women with and without prior prepregnancy or prenatal psychiatric hospitalizations.  Arch Gen Psychiatry. 2007;  64 42-48
• 7 Grof P, Robbins W, Alda M et al. Protective effect of pregnancy in women with lithium-responsive bipolar disorder.  J Affect Disord. 2000;  61 31-39
• 8 Cohen L S, Altshuler L L, Harlow B L et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment.  JAMA. 2006;  295 499-507
• 9 Viguera A C, Nonacs R, Cohen L S et al. Risk of recurrence of bipolar disorder in pregnant and nonpregnant women after discontinuing lithium maintenance.  Am J Psychiatry. 2000;  157 179-184
• 10 Viguera A C, Whitfield T, Baldessarini R J et al. Risk of recurrence in women with bipolar disorder during pregnancy: prospective study of mood stabilizer discontinuation.  Am J Psychiatry. 2007;  164 1817-1824
• 11 Milgrom J, Gemmill A W, Bilszta J L et al. Antenatal risk factors for postnatal depression: a large prospective study.  J Affect Disord. 2008;  108 147-157
• 12 Schaefer C, Spielmann H, Vetter K. et al .Arzneimittel in Schwangerschaft und Stillzeit. 8. Aufl München: Elsevier/Urban & Fischer; 2011
• 13 Lund N, Pedersen L H, Henriksen T B. Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes.  Arch Pediatr Adolesc Med. 2009;  163 949-954
• 14 Banach R, Boskovic R, Einarson T et al. Long-term developmental outcome of children of women with epilepsy, unexposed or exposed prenatally to antiepileptic drugs: a meta-analysis of cohort studies.  Drug Saf. 2010;  33 73-79
• 15 Zeskind P S, Stephens L E. Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior.  Pediatrics. 2004;  113 368-375
• 16 Rice F, Harold G T, Boivin J et al. The links between prenatal stress and offspring development and psychopathology: disentangling environmental and inherited influences.  Psychol Med. 2010;  40 335-345
• 17 Lee H C, Lin H C. Maternal bipolar disorder increased low birthweight and preterm births: a nationwide population-based study.  J Affect Disord. 2010;  121 100-105
• 18 Rohde A, Schaefer C. Psychopharmakotherapie in Schwangerschaft und Stillzeit. Arzneisicherheit – Beratung – Entscheidungsfindung. 3. Aufl Stuttgart: Thieme; 2010
• 19 Davis R L, Rubanowice D, McPhillips H et al. HMO Research Network Center for Education, Research in Therapeutics. Risks of congenital malformations and perinatal events among infants exposed to antidepressant medications during pregnancy.  Pharmacoepidemiol Drug Saf. 2007;  16 1086-1094
• 20 Ellfolk M, Malm H. Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs).  Reprod Toxicol. 2010;  30 249-260
• 21 Reis M, Källén B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data.  Psychol Med. 2010;  40 1723-1733
• 22 Pederson L H, Henriksen T B, Vestergaar M et al. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study.  BMJ. 2009;  339 b3569
• 23 Colvin L, Slack-Smith L, Stanley F J et al. Dispensing patterns and pregnancy outcomes for women dispensed selective serotonin reuptake inhibitors in pregnancy.  Birth Defects Res A Clin Mol Teratol. 2011;  91 142-152
• 24 Gentile S, Galbally M. Prenatal exposure to antidepressant medications and neurodevelopmental outcomes: a systematic review.  J Affect Disord. 2011;  128 1-9
• 25 Scialli A R, Iannucci A R. Whole embryo culture and the identification of “teratogenicity”.  Reprod Toxicol. 2010;  29 247-248
• 26 Hallberg P, Sjöblom V. The use of selective serotonin reuptake inhibitors during pregnancy and breast-feeding: a review and clinical aspects.  J Clin Psychopharmacol. 2005;  25 59-73
• 27 Oberlander T F, Warburton W, Misri S et al. Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data.  Birth Defects Res B Dev Reprod Toxicol. 2008;  83 68-76
• 28 Wichman C L, Moore K M, Lang T R et al. Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy.  Mayo Clin Proc. 2009;  84 23-27
• 29 Scialli A R. Paroxetine exposure during pregnancy and cardiac malformations.  Birth Defects Res A Clin Mol Teratol. 2010;  88 175-177
• 30 Rohde A, Dembinski J, Dorn C. Mirtazapine (Remergil) for treatment resistant hyperemesis gravidarum: rescue of a twin pregnancy.  Arch Gynecol Obstet. 2003;  268 (3) 219-221
• 31 Gentile S. Antipsychotic therapy during early and late pregnancy. A systematic review.  Schizophr Bull. 2010;  36 518-544
• 32 Reis M, Källén B. Maternal use of antipsychotics in early pregnancy and delivery outcome.  J Clin Psychopharmacol. 2008;  28 279-288
• 33 Yacobi S, Ornoy A. Is lithium a real teratogen? What can we conclude from the prospective versus retrospective studies? A review.  Isr J Psychiatry Relat Sci. 2008;  45 95-106
• 34 Harden C L, Meador K J, Pennell P B et al. Practice parameter update: management issues for women with epilepsy – focus on pregnancy: teratogenesis and perinatal outcomes.  Neurology. 2009;  73 133-141
• 35 Dolk H, Jentink J, Loane M et al. EUROCAT Antiepileptic Drug Working Group. Does lamotrigine use in pregnancy increase orofacial cleft risk relative to other malformations?.  Neurology. 2008;  71 714-722
• 36 Hunt S J, Craig J J, Morrow J I. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.  Neurology. 2009;  72 1108
• 37 Holmes L B, Baldwin E J, Smith C R et al. Increased frequency of isolated cleft palate in infants exposed to lamotrigine during pregnancy.  Neurology. 2008;  70 2152-2158
• 38 Vajda F J, Graham J E, Hitchcock A A et al. Is lamotrigine a significant human teratogen? Observations from the Australian Pregnancy Register.  Seizure. 2010;  19 558-561
• 39 Williams G, King J, Cunningham M et al. Fetal valproate syndrome and autism: additional evidence of an association.  Dev Med Child Neurol. 2001;  43 202-206
• 40 Matalon S, Schechtman S, Goldzweig G et al. The teratogenic effect of carbamazepine: a meta-analysis of 1255 exposures.  Reprod Toxicol. 2002;  16 9-17
• 41 Dolovich L R, Addis A, Vaillancourt J M et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies.  BMJ. 1998;  317 839-843